Comparative Pharmacology
Head-to-head clinical analysis: BRINSUPRI versus LISINOPRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRINSUPRI versus LISINOPRIL.
BRINSUPRI vs LISINOPRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRINSUPRI is a novel oral cyclin-dependent kinase (CDK) inhibitor that selectively inhibits CDK4 and CDK6, thereby blocking phosphorylation of the retinoblastoma (Rb) protein and preventing G1-to-S phase cell cycle progression. This induces cell cycle arrest in cancer cells with intact Rb function.
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor. It inhibits ACE, which converts angiotensin I to angiotensin II, a potent vasoconstrictor. This results in decreased plasma angiotensin II, leading to decreased vasoconstriction, reduced aldosterone secretion, decreased sodium and water retention, and lower blood pressure.
4 mg orally once daily, with or without food.
Initial: 5-10 mg orally once daily. Maintenance: 10-40 mg orally once daily. Max: 80 mg/day.
None Documented
None Documented
Clinical Note
moderateLisinopril + Etacrynic acid
"The risk or severity of adverse effects can be increased when Lisinopril is combined with Etacrynic acid."
Clinical Note
moderateLisinopril + Bumetanide
"The risk or severity of adverse effects can be increased when Lisinopril is combined with Bumetanide."
Clinical Note
moderateLisinopril + Benzydamine
"The risk or severity of adverse effects can be increased when Lisinopril is combined with Benzydamine."
Clinical Note
moderateLisinopril + Estrone sulfate
Terminal elimination half-life is approximately 20-30 hours in healthy adults, allowing once-daily dosing. In renal impairment (CrCl <30 mL/min), half-life may extend to >50 hours, requiring dose adjustment.
Terminal half-life approximately 12 hours (range 11–13 hours); clinical context: once-daily dosing for hypertension and heart failure; accumulation occurs with renal impairment.
Primarily renal excretion as unchanged drug (70-85%) and minor fecal elimination (10-15%). Biliary excretion accounts for <5%.
Renal: 100% unchanged via glomerular filtration and tubular secretion; negligible biliary/fecal elimination.
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor
"The serum concentration of Estrone sulfate can be decreased when it is combined with Lisinopril."